An analysis of Neisseria meningitidis strains causing meningococcal septic arthritis in England and Wales: 2010-2020.


Journal

The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424

Informations de publication

Date de publication:
10 2022
Historique:
received: 05 04 2022
revised: 22 07 2022
accepted: 25 07 2022
pubmed: 2 8 2022
medline: 14 9 2022
entrez: 1 8 2022
Statut: ppublish

Résumé

To analyze clinical meningococcal strains associated with meningococcal septic arthritis cases in England and Wales, and to identify associations between patient age, the synovial joint affected and strain characteristics. IMD cases confirmed by the Meningococcal Reference Unit (UK Health Security Agency) between January 2010 and December 2020 were included in the analysis. Septic arthritis cases were defined as those featuring detection and/or isolation of N. meningitidis from an articular site. Capsular grouping was performed by serology on clinical isolates and/or real-time PCR on clinical samples. We identified 162 cases of meningococcal septic arthritis, representing 2% of all invasive meningococcal disease cases during the study period. The knee and the hip were the most commonly affected joints, with the former significantly more frequent in adults and the latter seen more commonly in children and adolescents. Group B strains were between 2 and 6 times less likely to cause septic arthritis in relation to groups W, C and Y strains. Meningococcal septic arthritis remains a rare manifestation of invasive meningococcal disease. Strain and age associations identified in this study remain unexplained. Future analyzes including clinical case information may help to explain these findings.

Identifiants

pubmed: 35914608
pii: S0163-4453(22)00446-7
doi: 10.1016/j.jinf.2022.07.019
pii:
doi:

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

390-396

Informations de copyright

Copyright © 2022. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest GGB, SAC, AW, LW, LLW, JL, XB and RB have performed contract research on behalf of the UK Health Security Agency for Pfizer, GlaxoSmithKline and Sanofi-Pasteur, but received no personal renumeration. No other authors have any conflict of interest to declare.

Auteurs

George Gyamfi-Brobbey (G)

Vaccine Evaluation Unit, UK Health Security Agency, Manchester Royal Infirmary, Oxford Road, Manchester, United Kingdom.

Stephen A Clark (SA)

Meningococcal Reference Unit, UK Health Security Agency, Manchester Royal Infirmary, Oxford Road, Manchester, United Kingdom. Electronic address: Stephen.clark@phe.gov.uk.

Helen Campbell (H)

Immunisation and Countermeasures Division, UK Health Security Agency, 61 Colindale Avenue, London, United Kingdom.

Aiswarya Lekshmi (A)

Meningococcal Reference Unit, UK Health Security Agency, Manchester Royal Infirmary, Oxford Road, Manchester, United Kingdom.

Sonia Ribeiro (S)

Immunisation and Countermeasures Division, UK Health Security Agency, 61 Colindale Avenue, London, United Kingdom.

Andrew Walker (A)

Meningococcal Reference Unit, UK Health Security Agency, Manchester Royal Infirmary, Oxford Road, Manchester, United Kingdom.

Anna Mensah (A)

Immunisation and Countermeasures Division, UK Health Security Agency, 61 Colindale Avenue, London, United Kingdom.

Laura Willerton (L)

Meningococcal Reference Unit, UK Health Security Agency, Manchester Royal Infirmary, Oxford Road, Manchester, United Kingdom.

Lloyd Walsh (L)

Meningococcal Reference Unit, UK Health Security Agency, Manchester Royal Infirmary, Oxford Road, Manchester, United Kingdom.

Jay Lucidarme (J)

Meningococcal Reference Unit, UK Health Security Agency, Manchester Royal Infirmary, Oxford Road, Manchester, United Kingdom.

Xilian Bai (X)

Meningococcal Reference Unit, UK Health Security Agency, Manchester Royal Infirmary, Oxford Road, Manchester, United Kingdom.

Shamez N Ladhani (SN)

Immunisation and Countermeasures Division, UK Health Security Agency, 61 Colindale Avenue, London, United Kingdom.

Saad Ahmed (S)

Colchester Hospital, East Suffolk and North Essex NHS Trust, Turner Road, Mile End, Colchester, United Kingdom.

Tom Walton (T)

Colchester Hospital, East Suffolk and North Essex NHS Trust, Turner Road, Mile End, Colchester, United Kingdom.

Ray Borrow (R)

Vaccine Evaluation Unit, UK Health Security Agency, Manchester Royal Infirmary, Oxford Road, Manchester, United Kingdom; Meningococcal Reference Unit, UK Health Security Agency, Manchester Royal Infirmary, Oxford Road, Manchester, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH